Morning Overview on MSN
The first baby treated with a custom CRISPR therapy is thriving a year later
One year after receiving three doses of a custom-built CRISPR base-editing therapy at Children’s Hospital of Philadelphia, ...
CRISPR Therapeutics stock has rebounded in the short term; however, over five years the share price is still significantly ...
In late June 2026, CRISPR Therapeutics AG was added to several Russell growth indexes, including the Russell 2000 Growth, ...
CRISPR Therapeutics wins FDA pediatric approval for Casgevy, boosting market potential and pipeline upside despite slow uptake. Click here to read more.
A handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high ...
A handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high ...
6d
CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
From gene-editing breakthroughs to blockbuster cystic fibrosis drugs, these two industry leaders present sharply contrasting ...
New Scientist on MSN
I’m the first person whose life was saved by CRISPR base editing
When standard leukaemia treatments failed, 13-year-old Alyssa Tapley was told she had only weeks left – but then she was ...
The company seems to be doing everything it's supposed to be doing; the stock just isn't responding.
The use of genome editing in early embryos has pulled back the curtain on the role of one of the key genes that orchestrates ...
A team of researchers led by Professor Akitsu Hotta (Department of Clinical Application) developed a comprehensive framework ...
In a rapidly changing climate landscape, the plants we rely on for food, textiles and more face a multitude of challenges, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results